Quick Answer
IN8BIO, INC. reported Research And Development Expense of $10.21 million for the year ending 2025.
- IN8BIO, INC. showed a decrease of -39.8% in Research And Development Expense from 2024 to 2025.
- This data is from IN8BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.78 million | Q3 2020: $1.06 million | Q1 2021: $1.25 million | Q2 2021: $2.06 million | Q3 2021: $1.35 million | Q1 2022: $2.38 million | Q2 2022: $3.50 million | Q3 2022: $4.26 million | Q1 2023: $4.39 million | Q2 2023: $4.13 million | Q3 2023: $3.79 million | Q1 2024: $4.90 million | Q2 2024: $5.16 million | Q3 2024: $3.31 million | Q1 2025: $2.97 million | Q2 2025: $2.49 million | Q3 2025: $2.10 million.
- Over the full 6 years of available data (2020 to 2025), IN8BIO, INC.'s Research And Development Expense has grown by 89.9%.
- Historical annual values: Fiscal year 2025: $10.21 million | Fiscal year 2024: $16.96 million | Fiscal year 2023: $16.83 million | Fiscal year 2022: $14.06 million | Fiscal year 2021: $7.35 million | Fiscal year 2020: $5.38 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: